Strategic Partnership Sterling partners with Curative Biotechnology to manufacture clinical supply of a metformin-based topical ophthalmic formulation, indicating readiness for contract manufacturing of complex ophthalmic products and potential for expanded clinical supply collaborations.

Niche Expertise Specialization in technology transfers, scale-up, and commercial manufacturing positions Sterling as a go-to CM for late-stage development and scale-up, presenting opportunities to upsell process development and tech-transfer services for clients moving toward commercialization.

Financial Capacity With reported revenue in the mid-range of small-to-mid-sized contract manufacturers ($25M–$50M) Sterling demonstrates solid financial footing suitable for targeted multi-year manufacturing agreements and ramping capacity for growth opportunities.

Manufacturing Breadth Full-service pharmaceutical contract capabilities combined with a lean employee base suggest agility and potential for rapid onboarding of new projects, appealing to startups seeking scalable manufacturing partners with responsive support.

Market Position Operating in a landscape with large CM players and mid-tier firms, Sterling can compete on specialized tech-transfer and ophthalmic formulations, creating sales opportunities to capture niche pharma clients seeking focused, collaborative manufacturing partnerships.